Skip to Main Content

Issue Archive

In this Issue

Table of Contents

Ham-Wasserman Lecture

Acute Lymphoblastic Leukemia: Aiming High to Keep MRD Low, or Even Better, Negative

Aggressive Non-Hodgkin Lymphomas: It’s Getting Personal

Aging and Hematologic Disorders: Exploring the Evidence

Balancing the Scales: Management of Patients at Risk of Bleeding and Clotting in the Acute Care Setting

Bone Marrow Failure and Clonal Evolution

Challenges in Myeloma Therapy

Coagulation Conundrum Roundtable: Case-Based Discussion on the Implications of Exogenous Estrogens in Hemostasis and Thrombosis

Combined Basic Science and Education Session on Cancer-Associated Thrombosis

DOACs in the Real World

Expanding Horizons for Immunotherapy in Pediatric Leukemia

Hodgkin Lymphoma: Celebrating 200 Years since Thomas Hodgkin Entered Medicine

Immunotherapy in Myeloma

Indolent Lymphomas: The Marathon Has a New Course

Inflammation and Hematopoiesis: The Impact of Inflammation on the Bone Marrow Microenvironment

Iron: How to Manage When There Is Too Much or Too Little of It

Management of Sickle Cell Disease Complications Beyond Acute Chest

Myelodysplastic Syndromes: From Mild-Mannered to Lurking Leukemia

Myeloproliferative Neoplasms: Managing the Cup That Runneth Over

New Diagnostic and Treatment Strategies for Antiphospholipid Syndrome

Patients, Borders, Money, and Mission: A Global Perspective of Chronic Myeloid Leukemia

Primary Immunodeficiencies: Finding the Needle in the Haystack

Response Comes of Age in Chronic Lymphocytic Leukemia

Sickle Cell Disease in Young and Old: A Time for Re-Evaluation

Spoiled for Choice: Donor Selection for Allogeneic Stem Cell Transplantation

Therapy of Acute Myeloid Leukemia: Adapting to Change

Transfusion Medicine: Optimizing Patient Blood Management (PBM)

What's New in the Diagnosis and Management of von Willebrand Disease?

Why Patients Fail after Allogeneic Stem Cell Transplantation


  • Cover Image

    Cover Image

    issue cover

    T cells and brain cancer cell. The image is a composite colored scanning electron micrograph of T cells and an apoptotic brain cancer cell. T cells are a component of the body’s immune system. Chimeric antigen receptor (CAR) T-cell therapy takes T cells from a cancer patient’s blood and modifies them to recognize a specific protein found on the patient’s tumor cells. When reintroduced into the patient, the T cells find and destroy the tumor cells. The newest form of CAR T-cell therapy, now in clinical trials, uses “memory” T cells, which remain in the body after attacking the cancer. The hope is that memory T cells may provide an active reservoir of cancer-killing cells capable of stopping further tumors. Magnification ×6000 at 10 cm wide. Source: Steve Gschmeissner/Science Photo Library.

  • PDF Icon PDF LinkFront Matter
  • PDF Icon PDF LinkTable of Contents
Close Modal
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close Modal
Close Modal